Will These Analyst Moves Affect Vertex Pharmaceuticals (VRTX) Stock Today?

NEW YORK (TheStreet) -- A pair of analysts took action on Vertex Pharmaceuticals (VRTX) on Wednesday.

HC Wainwright downgraded Vertex to "neutral" from "buy" and set an $85 price target. The firm said the company's 809 drug still has scientific risks.

UBS, on the other hand, increased its price target to $115 and set a "buy" rating. The firm said price, heterozygotes and takeout potential are all drivers of upside.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 0.45% to $93.11 in pre-market trading on Wednesday.

VRTX Chart

VRTX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)